Company news
GT Biopharma, Inc. news in 2020
GT Biopharma, Inc.'s news releases, calls and decks from 2020, newest first.
GT Biopharma Announces TriKE™ For The Treatment Of Breast And GI Cancers
December 27, 2020
GT Biopharma announces FDA data - GTB-3550 TriKE™ reduces cancer cells by 61.7% for a high-risk myelodysplastic syndromes (HR-MDS) patient
December 20, 2020
GT Biopharma And Cytovance Biologics Announce Milestone Achievement
December 16, 2020
GT Biopharma Submits Application for Uplisting to the NASDAQ Capital Market
December 13, 2020
GT Biopharma Announces GTB-3550 TriKE(TM) Reduces Bone Marrow Blast Levels, Improves NK Cell Function and Proliferation, and No Toxicities Observed in AML and MDS Patients
December 7, 2020
GT Biopharma Announces Dr. Greg Berk, M.D. Joins Board of Directors
November 18, 2020
GT Biopharma Appoints Michael Handelman, CPA as Chief Financial Officer
November 17, 2020
GT Biopharma Announces Former Abraxis CEO, Bruce J. Wendel as Vice Chairman of GTBP Board of Directors
November 16, 2020
GT Biopharma Announces Publication of GTB-3550 TriKE Interim Results at the Prestigious 62nd American Society of Hematology (ASH) Annual Meeting
November 11, 2020
GT Biopharma Announces Publication of Trike(TM) Results Targeting Multiple B7H3 Positive Cancers
October 20, 2020
GT Biopharma Announces Selection of GTB-3550 Interim Results for Presentation at 62nd (ASH) American Society of Hematology Annual Meeting
October 14, 2020
GT Biopharma Announces Advisory Board Appointments
October 12, 2020
GT Biopharma Announces Expanded TriKE(TM) Partnership With Cytovance Biologics
October 5, 2020
GT Biopharma Announces GTB-3550 TriKE(TM) Phase I/II Clinical Trial Update
September 21, 2020
GT Biopharma Provides Update on Development of TriKE(TM) Therapeutic for Treatment of COVID-19 Infection
August 19, 2020
GT Biopharma Advances To Dose Level 3 with TriKE(TM) FDA Phase I/II Clinical Trial
August 3, 2020
GT Biopharma Announces Completion of $5.6 Million Bridge Financing
July 21, 2020
GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial
May 26, 2020
GT Biopharma Announces Commencement of Retreatment of Patient Demonstrating Successful Clinical Benefit following GTB-3550 TriKE(TM) therapy
March 30, 2020
GT Biopharma Announces Preliminary Results for GTB-3550 TriKE(TM) Phase I/II Clinical Trial for Treatment of Acute Myeloid Leukemia
March 18, 2020
GT Biopharma and Cytovance Biologics Announce Collaboration Agreement TriKE(TM) Therapeutic for Treatment of Coronavirus Infection
March 9, 2020
GT Biopharma Announces Dosing First Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial
February 25, 2020
GT Biopharma Provides Update Concerning Trike(TM) Drug Development Programs and Other Strategic Initiatives
January 20, 2020